JP2009502937A5 - - Google Patents

Download PDF

Info

Publication number
JP2009502937A5
JP2009502937A5 JP2008524094A JP2008524094A JP2009502937A5 JP 2009502937 A5 JP2009502937 A5 JP 2009502937A5 JP 2008524094 A JP2008524094 A JP 2008524094A JP 2008524094 A JP2008524094 A JP 2008524094A JP 2009502937 A5 JP2009502937 A5 JP 2009502937A5
Authority
JP
Japan
Prior art keywords
composition
compound
kinase
abl kinase
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008524094A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009502937A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/028984 external-priority patent/WO2007014250A2/en
Publication of JP2009502937A publication Critical patent/JP2009502937A/ja
Publication of JP2009502937A5 publication Critical patent/JP2009502937A5/ja
Pending legal-status Critical Current

Links

JP2008524094A 2005-07-26 2006-07-26 Ablキナーゼ阻害 Pending JP2009502937A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70277105P 2005-07-26 2005-07-26
US78516106P 2006-03-23 2006-03-23
US83025706P 2006-07-12 2006-07-12
PCT/US2006/028984 WO2007014250A2 (en) 2005-07-26 2006-07-26 Abl kinase inhibition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012122081A Division JP2012158616A (ja) 2005-07-26 2012-05-29 Ablキナーゼ阻害

Publications (2)

Publication Number Publication Date
JP2009502937A JP2009502937A (ja) 2009-01-29
JP2009502937A5 true JP2009502937A5 (cg-RX-API-DMAC7.html) 2009-09-10

Family

ID=37683933

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008524094A Pending JP2009502937A (ja) 2005-07-26 2006-07-26 Ablキナーゼ阻害
JP2012122081A Pending JP2012158616A (ja) 2005-07-26 2012-05-29 Ablキナーゼ阻害

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012122081A Pending JP2012158616A (ja) 2005-07-26 2012-05-29 Ablキナーゼ阻害

Country Status (6)

Country Link
US (1) US20090298844A1 (cg-RX-API-DMAC7.html)
EP (1) EP1906967A4 (cg-RX-API-DMAC7.html)
JP (2) JP2009502937A (cg-RX-API-DMAC7.html)
AU (1) AU2006272609A1 (cg-RX-API-DMAC7.html)
CA (1) CA2616517A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007014250A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007065124A2 (en) * 2005-12-01 2007-06-07 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting complex karyotypes
EP2051737A2 (en) * 2006-07-26 2009-04-29 Merck & Co., Inc. A novel lactic acid formulation of mk-0457 useful for the treatment of cancer
SG11201406584TA (en) 2012-04-24 2014-11-27 Vertex Pharma Dna-pk inhibitors
RS62649B1 (sr) 2013-03-12 2021-12-31 Vertex Pharma Inhibitori dnk-pk
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
KR102411227B1 (ko) 2013-10-17 2022-06-21 버텍스 파마슈티칼스 인코포레이티드 Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정
MA38393B1 (fr) 2014-03-13 2018-11-30 Sanofi Sa Composés hétéroaryle et utilisations associées
MX394860B (es) 2016-09-27 2025-03-24 Vertex Pharma Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2341133A1 (en) * 2001-10-05 2011-07-06 Novartis AG Mutated Abl kinase domains
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
BRPI0515012A (pt) * 2004-08-13 2008-07-01 Genentech Inc substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso

Similar Documents

Publication Publication Date Title
CA2869269C (en) Use of ccr3-inhibitors
CN103402514B (zh) 用于治疗运动障碍的血清素受体激动剂组合物
JP2005506370A5 (cg-RX-API-DMAC7.html)
JP2013507415A5 (cg-RX-API-DMAC7.html)
NO20081843L (no) Farmasoytisk sammensetning for forbedret kognitiv funksjon
FI3952880T3 (fi) 2-(2,6-dioksopiperidin-3-yyli)-4-((2-fluori-4-((3-morfolinoatsetidin-1-yyli)metyyli)bentsyyli)amino)isoindoliini-1,3-dioni käytettäväksi non-hodgkinin lymfooman hoidossa
BRPI0506765A (pt) composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição
JP2010529118A5 (cg-RX-API-DMAC7.html)
EA201692214A1 (ru) Вещества, связывающие ядерные рецепторы
ITBO20110012A1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
JP2019511489A5 (cg-RX-API-DMAC7.html)
WO2009066152A3 (en) Haloallylamine inhibitors of ssao/vap-1 and uses therefor
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
JP2012508734A5 (cg-RX-API-DMAC7.html)
JP2018090566A5 (cg-RX-API-DMAC7.html)
JP2009062388A5 (cg-RX-API-DMAC7.html)
JP2009541409A5 (cg-RX-API-DMAC7.html)
JP2007501270A5 (cg-RX-API-DMAC7.html)
EA200800783A1 (ru) Композиция тразодона для введения один раз в день
NO20065152L (no) Formulering med vedvarende frigivelse for oral administrering av HMG-COA-reduktaseinhibitor, og fremgansmate for fremstilling derav
JP2008513426A5 (cg-RX-API-DMAC7.html)
JP2010539130A5 (cg-RX-API-DMAC7.html)
JP2008533021A5 (cg-RX-API-DMAC7.html)
CN109069466A (zh) 5-ht6受体拮抗剂用于治疗阿尔茨海默病伴情感淡漠共病
ATE506941T1 (de) Behandlung psychiatrischer patienten mit schlafstörungen und/oder übermässiger tagesschläfrigkeit mit paliperidon